MIRM — Mirum Pharmaceuticals, Inc. stock price, charts and financials

QT64Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
98.01
-2.64-2.62%
OverviewShort InterestFilings
MIRMQT64Mirum Pharmaceuticals, Inc.·NASDAQ
98.01-2.62%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
XENE-0.23%$63.22PTCT+0.31%$73.54CNTA+0.00%$40.50ORKA+3.92%$102.69SRRK-3.33%$51.16ERAS-2.39%$17.97LGND-1.25%$289.48CAI+1.17%$23.00
Snapshot
Index-P/E-EPS (ttm)-13.62Insider Own43.05%Shs Outstand60.98MPerf Week-5.00%
Market Cap6.14BForward P/E-EPS next Y-0.78Insider Trans-0.59%Shs Float52.46MPerf Month-21.18%
Enterprise Value6.57BPEG0.00EPS next Q-Inst Own-Short Float13.86%Perf Quarter-2.22%
Income-827.98MP/S9.93EPS this Y-11.48%Inst Trans-Short Ratio7.37Perf Half Y2.46%
Sales618.07MP/B-EPS next Y94.89%ROA-82.32%Short Interest7.27MPerf YTD27.42%
Book/sh-P/C-EPS next 5Y-ROE-410.20%52W High126.60 -22.58%Perf Year88.52%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-13.09%52W Low53.31 83.84%Perf 3Y303.89%
Dividend Est.-EV/EBITDA-Sales past 3/5Y89.14% -Gross Margin81.70%Volatility5.01% 4.44%Perf 5Y596.54%
Dividend TTM-EV/Sales10.63EPS Y/Y TTM-636.22%Oper. Margin-17.42%ATR (14)5.90Perf 10Y-
Dividend Ex-Date-Quick Ratio2.74Sales Y/Y TTM69.14%Profit Margin-139.18%RSI (14)39.34Recom1.94
Dividend Gr. 3/5Y-Current Ratio2.86EPS Q/Q-4376.67%SMA20-9.92%Beta0.49Target Price138.30
Payout0.00%Debt/Eq-Sales Q/Q42.86%SMA50-8.26%Rel Volume0.86Prev Close100.65
Employees372LT Debt/Eq1.01EarningsNov 03SMA2007.99%Avg Volume973.22KPrice98.01
IPO DateJul 18, 2019Option/ShortYes / YesEPS/Sales Surpr.-3576.73% 7.89%Net Debt/EBITDA-0.55Volume838,972Change-2.62%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-06-26ReiteratedRobert W. Baird$129 → $123
Aug-06-26ReiteratedMorgan StanleyOverweight$150 → $137
Aug-06-26ReiteratedRBC CapitalOutperform$148 → $135
Aug-06-26ReiteratedHC Wainwright & Co.Buy$185 → $140
Jul-07-26ReiteratedRBC CapitalOutperform$142 → $148
Jun-15-26ReiteratedCLSA$146
Jun-11-26ReiteratedMorgan StanleyOverweight$140 → $150
May-19-26InitiatedWolfe ResearchOutperform$145
May-07-26ReiteratedRaymond JamesStrong Buy$164 → $165
May-07-26ReiteratedH.C. WainwrightBuy$175 → $185
Latest News
Aug-06-26
Aug-06-2612:26PM
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raisedzacks.com
Aug-05-26
Aug-05-2611:40PM
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcriptseekingalpha.com
11:04PM
Mirum Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
09:04PM
Mirum Pharmaceuticals (NASDAQ:MIRM) Slides on Wider Loss and Volixibat Delay Despite Revenue BeatChartMill
07:01PM
Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metricszacks.com
06:26PM
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimateszacks.com
04:01PM
Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Updatebusinesswire.com
Jul-29-26
Jul-29-2604:01PM
Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026businesswire.com
Jul-16-26
Jul-16-2608:45AM
Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology AheadSeekingAlpha
Jul-13-26
Jul-13-2604:01PM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com
Jul-08-26
Jul-08-2608:10PM
Stocks To Watch: 14 Names Test And Tease New Buy ZonesYahoo
Jul-07-26
Jul-07-2610:28AM
SBIO: Biotech Breakthrough Opportunities Screened For Cash BurnSeekingAlpha
Jul-04-26
Jul-04-2603:48AM
Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolioseekingalpha.com
Jun-29-26
Jun-29-2611:56AM
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?zacks.com
Jun-15-26
Jun-15-2610:06AM
Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $146Benzinga
Company

Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue618521337——————
Cost of Goods Sold Incl. D&A11310182——————
Gross Profit505421255——————
Selling, General and Administrative Excl. Other313257202——————
Research and Development283186141——————
Other Operating Expense
1600——————
Operating Income-108-22-88——————
Interest Expense151414——————
Unusual Expense
—————————
Non-Operating Income (Expense)-7361515——————
Net Income Before Taxes-858-21-87——————
Income Taxes321——————
Consolidated Net Income-860-23-88——————
Net Income From Continuing Operations-860-23-88——————
Net Income-860-23-88——————
EPS (Recurring)-14.55-0.47-1.85——————
EPS (Basic, Before Extraordinaries)-14.55-0.47-1.85——————
EPS (Diluted)-14.56-0.47-1.85——————
EBITDA-77617-49——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio9.997.585.89——————
Gross Margin81.7280.8175.67——————
Operating Margin-17.48-4.22-26.11——————
Net Margin-139.16-4.41-26.11——————
Shares Outstanding635048——————
Market Capitalization6,1753,9491,985——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$141.26$113.77$86.28$58.80$31.31● Close Price0.00M2.25M4.50M6.75M9.00MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Howe JolandaSVP, GLOBAL CONTROLLERAug 03 '26Sale105.291,840193,7341,274Aug 05
BJERKHOLT ERICCHIEF FINANCIAL OFFICERJul 06 '26Sale122.255,000611,27442,181Jul 08
Peetz ChristopherCHIEF EXECUTIVE OFFICERJul 06 '26Option Exercise2.9420,00058,720214,309Jul 08
Peetz ChristopherCHIEF EXECUTIVE OFFICERJul 06 '26Sale122.2720,0002,445,383194,309Jul 08
Howe JolandaSVP, GLOBAL CONTROLLERJul 01 '26Sale120.002,721326,5203,114Jul 02
Howe JolandaSVP, GLOBAL CONTROLLERJun 17 '26Sale101.952,594264,4585,835Jun 18
BJERKHOLT ERICCHIEF FINANCIAL OFFICERJun 09 '26Option Exercise26.492,39363,39147,181Jun 09
BJERKHOLT ERICCHIEF FINANCIAL OFFICERJun 08 '26Sale93.825,000469,07744,788Jun 09
Radovich PeterPRESIDENT AND COOJun 05 '26Option Exercise19.1916,988326,00057,260Jun 08
Peetz ChristopherCHIEF EXECUTIVE OFFICERJun 01 '26Sale95.8430,0002,875,103194,309Jun 02
Peetz ChristopherCHIEF EXECUTIVE OFFICERJun 01 '26Option Exercise2.9430,00088,080224,309Jun 02
Ramasastry SairaDirectorJun 01 '26Sale100.003,977397,7000Jun 02
Cardon LonDirectorMay 29 '26Option Exercise0.003,97709,680Jun 02
Ramasastry SairaDirectorMay 29 '26Option Exercise0.003,97703,977Jun 02
Fischer LaurentDirectorMay 29 '26Option Exercise0.003,977010,727Jun 02
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.